# Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older

> **NCT02735915** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 70 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Herpes Zoster Vaccine GSK1437173A

## Key facts

- **NCT ID:** NCT02735915
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-11
- **Primary completion:** 2017-08-28
- **Final completion:** 2018-10-08
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02735915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02735915, "Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02735915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*